Ignite Creation Date:
2024-05-06 @ 1:43 PM
Last Modification Date:
2024-10-26 @ 1:19 PM
Study NCT ID:
NCT04109482
Status:
TERMINATED
Last Update Posted:
2023-06-22
First Post:
2019-09-25
Brief Title:
Trial to Evaluate the Safety and Efficacy of MB-102 in Patients With BPDCN
Sponsor:
Mustang Bio
Organization:
Mustang Bio
Study Overview
Official Title:
A Phase 12 Open Label Multicenter Trial to Assess the Safety and Efficacy of MB-102 in Patients With Relapsed or Refractory Blastic Plasmacytoid Dendritic Cell Neoplasm
Status:
TERMINATED
Status Verified Date:
2023-06
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Business reasons
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
A phase 12 study to assess the safety and efficacy of MB-102 in patients with relapsed or refractory BPDCN
Detailed Description:
The Phase 1 portion of the study will determine the maximum tolerated dose of MB-102
The Phase 2 portion of the trial will evaluate the efficacy of MB-102 in relapsed or refractory BPDCN
The Phase 2 portion of the trial will evaluate the efficacy of MB-102 in relapsed or refractory BPDCN
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None